Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H26N6O |
Molecular Weight | 426.5135 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5)C(=O)CCCC2
InChI
InChIKey=KCTFTBCZZUBAKN-UHFFFAOYSA-N
InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
Molecular Formula | C25H26N6O |
Molecular Weight | 426.5135 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pratosartan is an orally active angiotensin II type 1 receptor blocker. It is being developed for the treatment of hypertension. Pratosartan was efficacious throughout the long-term study, without serious adverse effects. Pratosartan significantly decreased serum total cholesterol in patients with hypercholesterolemia and uric acid in patients with hyperuricemia. It may have beneficial effects on hypertensive patients with some metabolic disorders. Pratosartan is still in phase III development in South Korea and phase II in Japan for hypertension.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Antihypertensive effect of chronic KT3-671, a structurally new nonpeptide angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. | 1995 Nov |
|
Synthesis and pharmacological activity of the metabolites of Pratosartan. | 2006 Jun |
|
Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3h-cycloheptimidazol-4-ones and 2-alkyl-3h-cycloheptimidazol-4-ones. | 2006 May |
|
Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. | 2007 Jan |
|
Effects of angiotensin II receptor blockers on renal handling of uric acid in rats. | 2008 |
|
Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. | 2008 Feb |
|
Gateways to clinical trials. July-August 2008. | 2008 Jul-Aug |
|
Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. | 2008 Mar |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:15:51 UTC 2022
by
admin
on
Fri Dec 16 18:15:51 UTC 2022
|
Record UNII |
66VLQ6E6DL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66930
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
32041
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
153804-05-8
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
C528642
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
66VLQ6E6DL
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
CHEMBL41194
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
8100
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
DTXSID90934820
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
9802561
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY | |||
|
C72935
Created by
admin on Fri Dec 16 18:15:51 UTC 2022 , Edited by admin on Fri Dec 16 18:15:51 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |